Osteocytes are terminally differentiated cells of the osteoblast lineage. They are involved in the regulation of bone remodeling by increasing osteoclast formation or decreasing bone formation by the secretion of the osteoblast inhibitor sclerostin. Monoclonal antibody anti-sclerostin, Romosozumab, has been developed and tested in clinical trials in patients with osteoporosis. In the last years, the role of osteocytes in the development of osteolytic bone lesions that occurs in multiple myeloma, have been underlined. Myeloma cells increase osteocyte death through the up-regulation of both apoptosis and autophagy that, in turn, triggers osteoclast formation, and activity. When compared to healthy controls, myeloma patients with bone disease have higher osteocyte cell death, but the treatment with proteasome inhibitor bortezomib has been shown to maintain osteocyte viability. In preclinical mouse models of multiple myeloma, treatment with blocking anti-sclerostin antibody increased osteoblast numbers and bone formation rate reducing osteolytic bone lesions. Moreover, the combination of anti-sclerostin antibody and the osteoclast inhibitor zoledronic acid increased bone mass and fracture resistance synergistically. However, anti-sclerostin antibody did not affect tumor burden in vivo or the efficacy of antimyeloma drugs in vitro. Nevertheless, the combination therapy of antisclerostin antibody and the proteasome inhibitor carfilzomib, displayed potent anti-myeloma activity as well as positive effects on bone disease in vivo. In conclusion, all these data suggest that osteocytes are involved in myeloma bone disease and may be considered a novel target for the use of antibody-mediated anti-sclerostin therapy also in multiple myeloma patients.

Role of osteocytes in myeloma bone disease: Anti-sclerostin antibody as new therapeutic strategy / Toscani, Denise; Bolzoni, Marina; Ferretti, Marzia; Palumbo, Carla; Giuliani, Nicola. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 9:OCT(2018), pp. 2467-2467. [10.3389/fimmu.2018.02467]

Role of osteocytes in myeloma bone disease: Anti-sclerostin antibody as new therapeutic strategy

TOSCANI, DENISE;Ferretti, Marzia;Palumbo, Carla;GIULIANI, NICOLA
2018

Abstract

Osteocytes are terminally differentiated cells of the osteoblast lineage. They are involved in the regulation of bone remodeling by increasing osteoclast formation or decreasing bone formation by the secretion of the osteoblast inhibitor sclerostin. Monoclonal antibody anti-sclerostin, Romosozumab, has been developed and tested in clinical trials in patients with osteoporosis. In the last years, the role of osteocytes in the development of osteolytic bone lesions that occurs in multiple myeloma, have been underlined. Myeloma cells increase osteocyte death through the up-regulation of both apoptosis and autophagy that, in turn, triggers osteoclast formation, and activity. When compared to healthy controls, myeloma patients with bone disease have higher osteocyte cell death, but the treatment with proteasome inhibitor bortezomib has been shown to maintain osteocyte viability. In preclinical mouse models of multiple myeloma, treatment with blocking anti-sclerostin antibody increased osteoblast numbers and bone formation rate reducing osteolytic bone lesions. Moreover, the combination of anti-sclerostin antibody and the osteoclast inhibitor zoledronic acid increased bone mass and fracture resistance synergistically. However, anti-sclerostin antibody did not affect tumor burden in vivo or the efficacy of antimyeloma drugs in vitro. Nevertheless, the combination therapy of antisclerostin antibody and the proteasome inhibitor carfilzomib, displayed potent anti-myeloma activity as well as positive effects on bone disease in vivo. In conclusion, all these data suggest that osteocytes are involved in myeloma bone disease and may be considered a novel target for the use of antibody-mediated anti-sclerostin therapy also in multiple myeloma patients.
24-ott-2018
9
OCT
2467
2467
Role of osteocytes in myeloma bone disease: Anti-sclerostin antibody as new therapeutic strategy / Toscani, Denise; Bolzoni, Marina; Ferretti, Marzia; Palumbo, Carla; Giuliani, Nicola. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 9:OCT(2018), pp. 2467-2467. [10.3389/fimmu.2018.02467]
Toscani, Denise; Bolzoni, Marina; Ferretti, Marzia; Palumbo, Carla; Giuliani, Nicola
File in questo prodotto:
File Dimensione Formato  
Frontiers_Immunology-09-02467.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 2.48 MB
Formato Adobe PDF
2.48 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1172562
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 26
  • ???jsp.display-item.citation.isi??? ND
social impact